Abstract: Embodiments relate to a modified cell comprising an antigen binding molecule, and the expression and/or function of one or more genes in the modified cell has been enhanced or reduced or eliminated. The one or more genes include CXCR3, SLC1A3, YAP, TIGIT, S1P1, and IL-35. In embodiments, the cell is a T cell, a dendritic cell, a NK cell, or a macrophage cell. In embodiments, the antigen binding molecule comprises a chimeric antigen receptor (CAR) and/or the second antigen binding molecule is a T Cell Receptor (TCR).

Abstract: Embodiments of the present disclosure include a method for treating Systemic Lupus Erythematosus (SLE) using CD19 CAR T cells. The method includes administering to the human patient a pharmaceutically effective amount of a population of T cells of the human patient that express a chimeric antigen receptor (CAR) that comprises the amino acid sequence of, e.g., SEQ ID NO: 23.

Abstract: The present disclosure relates to compositions and methods for enhancing cell response and/or expanding chimeric antigen receptor (CAR) cells and/or maintenance in vivo and/or in vitro. In embodiments, the method comprises obtaining CAR T cells comprising a CAR comprising a binding domain that binds a solid tumor antigen, a transmembrane domain, and an intracellular domain; and contacting the CART cells with white blood cells and a bispecific antibody, such as a Bispecific T cell engager (BiTE®), thereby activating the CAR T cells, wherein the level of activation of the CAR T cells is higher than the level of activation of CAR T ells that are contacted with B cells without the bispecific antibody. The bispecific antibody comprises a first binding domain binding CD3 and a second binding domain binding CD19, CD20, CD22, or BCMA.

Abstract: The present disclosure relates to a system for immune therapy, the system comprising a sample processing module configured to obtain whole blood from a subject; a cell incubation module configured to activate blood cells of the whole blood and/or introduce a vector into the blood cells of the whole blood; and a cell infusion module configured to infuse at least a portion of the whole blood to the subject, wherein the blood cells comprise CD3+ cells, NK cells, myeloid cells, and neutrophils.

Abstract: Methods related to wireless communication systems and scheduling channel state information operations and transmissions. A user equipment (UE) receives, from a base station (BS), a channel state information (CSI) computation request. The UE then identifies a first CSI measurement resource based on the CSI computation request. The UE determines CSI based on the first CSI measurement resource, and receives, from the BS, a CSI report transmission request associated with the first CSI measurement resource. The UE optionally transmits to the BS a CSI report based on the first CSI measurement resource or a different CSI measurement resource. Other features are also claimed and described.

Abstract: Various aspects of the present disclosure generally relate to wireless communication. In some aspects, a user equipment (UE) may transmit a communication that identifies one or more UE capability parameters for at least one of sounding reference signal reference signal received power measurement or cross-link interference (CLI) received signal strength indication measurement. The UE may receive a CLI measurement configuration that is based at least in part on the one or more UE capability parameters. Numerous other aspects are provided.

Abstract: Apparatus and associated methods relate to a one-piece structure for a solid electrolyte chemical sensor (SECS) having a first surface defining a cavity designed to receive a substrate that retains a solid electrolyte, an internal water impermeable coating on at least a portion of the first surface, a second surface that is substantially coplanar with an adjacent peripheral edge of a top surface of the substrate when the substrate is received in the cavity, and a plurality of electrical contacts disposed on the second surface adapted to electrically couple with the electrodes on the substrate when the substrate is received in the cavity and electrical paths are provided between respective electrical contacts and electrodes. In an illustrative example, the internal water impermeable coating may include a metallic material, such as gold. In various embodiments, the one-piece structure may advantageously prevent water loss from both the sensor substrate and the SECS.

Abstract: Methods, apparatuses and systems for providing gas detecting apparatuses (e.g., electrochemical detectors) are disclosed herein. An example gas detecting apparatus may comprise a sensing component comprising: a housing configured to receive a sample gaseous substance comprising a target gaseous substance and an interferent gaseous substance; a reference electrode, disposed within the housing; a counter electrode disposed within the housing; and a sensing electrode disposed within the housing that is operatively coupled to a bias voltage circuit.

Abstract: The present disclosure relates to compositions and methods for enhancing T cell response in vivo. For example, a method of enhancing T cell response in a subject or treating a subject having cancer, the method comprising: administering an effective amount of a composition comprising modified cells to the subject having a form of cancer associated with or expressing an antigen, for example, a solid tumor antigen; and administering (1) a nucleic acid encoding the antigen, (2) additional modified cells comprising the nucleic acid or the antigen, or (3) microorganisms, for example cold viruses, comprising the nucleic acid or the antigen. In embodiments, the modified cells comprise mixed cells targeting a solid tumor antigen and a white blood cell (WBC) antigen. In embodiments, the modified cells comprise a dominant negative form of an immune checkpoint molecule (e.g., PD-1). In embodiments, the modified cells comprise an exogenous polynucleotide encoding a therapeutic agent, such as IL-12 and IFN?.

Abstract: Methods, apparatuses and systems for providing gas detecting apparatuses (e.g., electrochemical detectors) are disclosed herein. An example gas detecting apparatus may comprise a sensing component comprising: a first sensing electrode configured to generate a first concentration level indication associated with a first portion of a sample gaseous substance disposed within the sensing component; and a second sensing electrode operatively coupled to a filtering element that is configured to absorb at least one substance from the sample gaseous substance, wherein the second sensing electrode is configured to generate a second concentration level indication associated with a second portion of the sample gaseous substance.

Abstract: The compositions and methods described herein are directed to treating solid tumors using CAR T therapy and/or antibodies targeting GCC. The compositions include CAR comprising an extracellular domain that binds GCC.

Abstract: Certain aspects of the present disclosure provide techniques for channel state information (CSI) processing occupation determination that can be used even in multiple transmission reception point (mTRP) scenarios. A method that may be performed by a user equipment (UE) includes receiving a channel state information (CSI) reporting configuration configuring the UE with a plurality of CSI reference signal (CSI-RS) resources for channel measurement (CMRs). The method includes determining a number of occupied CSI processing units, a number of occupied active CSI resources, and/or a number of occupied active CSI-RS ports based on an actual number of CSI measurements. The method includes performing CSI measurement based on the determination.

Abstract: A docker image is received. The docker image is for a container. The container contains files that allow for virtualization of applications that run within the container. The docker image is parsed to identify layer files in the docker image. Installed software components (e.g., installed files) and/or hardware components in the layer files are identified. Software application index calls are made to generate information that identifies relationships between the installed software components and/or hardware components. The relationships between the installed software components and/or hardware components are then displayed to a user.

Abstract: A user equipment (UE) includes: a transceiver configured to receive positioning signals; a memory; and a processor, communicatively coupled to the transceiver and the memory, configured to: send, via the transceiver to a network entity, a capability indication that includes a first positioning-method indication indicating that the processor supports simultaneous processing of a first combination of positioning methods; and simultaneously process one or more first positioning signals in accordance with the first combination of positioning methods to determine first position information for the UE.

Abstract: The present disclosure relates to systems and methods for immune therapy. For example, a method can be used to enhance proliferation of chimeric antigen receptor (CAR) T cells in a patient, The method comprises administering to the patient an effective amount of a pharmaceutical composition comprising lymphocyte activation agents and one or more recombinant viral particles comprising a polynucleotide encoding a CAR, wherein the proliferation of CAR T cells in the patient is greater as compared to a patient administered with the one or more recombinant viral particles but without the lymphocyte activation agents.

Abstract: Embodiments described herein relate to compositions including genetically modified CAR cells and uses thereof for treating cancer. Some embodiments of the present disclosure relate to compositions and methods for T cell response enhancement and/or CAR cell preparation. For example, a method may include obtaining cells comprising a CAR and culturing the cells in the presence of an agent that is recognized by the extracellular domain of the CAR.

Abstract: Apparatus and associated methods relate to a one-piece structure for a solid electrolyte chemical sensor (SECS) having a first surface defining a cavity (210, 305, 415) designed to receive a substrate (215, 350, 410) that retains a solid electrolyte (365, 440), an internal water impermeable coating (425) on at least a portion of the first surface, a second surface that is substantially coplanar with an adjacent peripheral edge of a top surface of the substrate (215, 350, 410) when the substrate (215, 350, 410) is received in the cavity (210, 305, 415), and a plurality of electrical contacts (335, 340, 345, 450a-450b) disposed on the second surface adapted to electrically couple with the electrodes (435a-435c) on the substrate (215, 350, 410) when the substrate (215, 350, 410) is received in the cavity (210, 305, 415) and electrical paths are provided between respective electrical contacts (335, 340, 345, 450a-450b) and electrodes (435a-435c).

Abstract: A method is implemented in a digital unit connected with a plurality of distributed antennas including a first antenna, a second antenna and a third antenna. The method comprises: causing transmitting a first signal from the first antenna, a second signal from the second antenna, and a third signal from the third antenna in a same frequency resource; obtaining a receiver and transmitter side loop-back phase difference between the first antenna and the second antenna based on the first signal received at the third antenna, the second signal received at the third antenna, the third signal received at the first antenna, and the third signal received at the second antenna; and obtaining estimations of a time delay difference and an initial phase difference between the first and second antennas based on the obtained loop-back phase difference.

Abstract: The compositions and methods described herein are directed to treating solid tumor using CAR T therapy. The compositions include CAR comprising an extracellular domain that binds a siglec protein or a receptor that binds the peptide hormone kisspeptin.

Abstract: Compositions and methods for enhancing T cell response which increases the efficacy of CAR T cell therapy for treating cancer are described. Embodiments include a modified cell comprising an isolated nucleic acid comprising a first nucleic acid and a second nucleic acid, the first nucleic acid encoding a chimeric antigen receptor (CAR), the second nucleic acid encoding a therapeutic agent comprising at least one of IFN-?, IL-2, IL-6, IL-7, IL-15, IL-17, and IL-23. The modified cell expresses and secretes the therapeutic agent.